


PHARMACEUTICAL 2023

## ALIMERA SCIENCES INC Rank 332 of 446









PHARMACEUTICAL 2023



ALIMERA SCIENCES INC Rank 332 of 446

The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 99% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Assets, Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 76% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	29,413
Cost of Goods Sold	0
Intangible Assets	8,957
Liabilities, Current	39,732
Liabilities, Non-Current	0
Other Assets	1,707
Other Compr. Net Income	-1,106
Other Expenses	42,579
Other Liabilities	0
Other Net Income	-558
Other Revenues	54,129
Property and Equipment	2,525
Research and Development	16,228
Selling, General and Administrative Expense	12,871

Output Variable	Value in 1000 USD
Assets	42,602
Liabilities	39,732
Expenses	71,678
Revenues	54,129
Stockholders Equity	2,870
Net Income	-18,107
Comprehensive Net Income	-18,660
Economic Capital Ratio	-33%

